RTW INVESTMENTS, LP: PROTAGONIST THERAPEUTICS INC (PTGX): Quarterly 13F Position History
As of Q1 2026, RTW INVESTMENTS, LP reported 5,059,053 shares of PROTAGONIST THERAPEUTICS INC (PTGX), worth $533.2M and representing 5.3% of its 13F equity book. The position first appeared in Q3 2019 and has been disclosed across 27 13F-HR filings in Pactolio's tracked window.
- 5,059,053Shares Held (Latest Filing)
- $533.2MReported Market Value (Latest Filing)
- 5.3%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$91.4MQuarter-over-Quarter Value Change
- 5,756,277Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 27 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 5,059,053 | 0 | — | $533.2M | 5.3% | $105.4 |
| Q4 2025 | 5,059,053 | 697,224 | -12.1% | $441.9M | 4.4% | $87.3 |
| Q3 2025 | 5,756,277 | 0 | — | $382.4M | 4.7% | $66.4 |
| Q2 2025 | 5,756,277 | +36,862 | +0.6% | $318.1M | 4.5% | $55.3 |
| Q1 2025 | 5,719,415 | +220,870 | +4.0% | $276.6M | 4.2% | $48.4 |
| Q4 2024 | 5,498,545 | +72,433 | +1.3% | $212.2M | 3.2% | $38.6 |
| Q3 2024 | 5,426,112 | +139,708 | +2.6% | $244.2M | 3.5% | $45.0 |
| Q2 2024 | 5,286,404 | 29,110 | -0.5% | $183.2M | 2.8% | $34.6 |
| Q1 2024 | 5,315,514 | 0 | — | $153.8M | 2.3% | $28.9 |
| Q4 2023 | 5,315,514 | 100,000 | -1.8% | $121.9M | 1.9% | $22.9 |
| Q3 2023 | 5,415,514 | 0 | — | $90.3M | 1.9% | $16.7 |
| Q2 2023 | 5,415,514 | +814,715 | +17.7% | $149.6M | 2.8% | $27.6 |
| Q1 2023 | 4,600,799 | +1,008,813 | +28.1% | $105.8M | 2.2% | $23.0 |
| Q4 2022 | 3,591,986 | 584,851 | -14.0% | $39.2M | 0.8% | $10.9 |
| Q3 2022 | 4,176,837 | 617,662 | -12.9% | $35.2M | 0.8% | $8.4 |
| Q2 2022 | 4,794,499 | 0 | — | $37.9M | 1.0% | $7.9 |
| Q1 2022 | 4,794,499 | +2,194,677 | +84.4% | $113.5M | 2.3% | $23.7 |
| Q4 2021 | 2,599,822 | +846,127 | +48.2% | $88.9M | 1.3% | $34.2 |
| Q3 2021 | 1,753,695 | 1,753,695 | -50.0% | $31.1M | 0.5% | $17.7 |
| Q2 2021 | 3,507,390 | 0 | — | $157.4M | 2.4% | $44.9 |
| Q1 2021 | 3,507,390 | 142,679 | -3.9% | $90.8M | 1.4% | $25.9 |
| Q4 2020 | 3,650,069 | +241,108 | +7.1% | $73.6M | 1.2% | $20.2 |
| Q3 2020 | 3,408,961 | +25,753 | +0.8% | $66.6M | 1.6% | $19.5 |
| Q2 2020 | 3,383,208 | +722,816 | +27.2% | $59.7M | 1.7% | $17.7 |
| Q1 2020 | 2,660,392 | +200,404 | +8.1% | $18.8M | 0.8% | $7.1 |
| Q4 2019 | 2,459,988 | +1,697,705 | +222.7% | $17.3M | 0.7% | $7.0 |
| Q3 2019 | 762,283 | — | — | $9.2M | 0.5% | $12.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did RTW INVESTMENTS, LP first disclose a PTGX position in 13F-HR filings?
RTW INVESTMENTS, LP first reported PROTAGONIST THERAPEUTICS INC (PTGX) on its 13F-HR filing for the period ending 2019-09-30 (Q3 2019). The position has appeared on 27 reported quarters within Pactolio's tracked window.
What was RTW INVESTMENTS, LP's most recent quarter-over-quarter share-count change in PTGX?
RTW INVESTMENTS, LP held the same 5,059,053 shares of PTGX between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent RTW INVESTMENTS, LP's cost basis in PTGX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.